Advertisement

Cholinergic Mechanisms in Mental Illness: Anticholinergic Hallucinogens

  • Max Fink

Abstract

For more than half a century, hallucinogenic substances have intrigued experimentalists seeking to understand the peculiar perceptual disturbances and thought disorders of the insane. Early studies of mescaline, opium alkaloids, and morphine have been followed more recently by interest in the amphetamines, LSD, and psilocybin. A special enthusiam for LSD was generated in many observers who ascribed significance to its ability in uniquely small quantities to stimulate perceptual distortions without confusion or disorientation, simulating naturally occurring psychoses. The mode of action of LSD and mescaline was related to the effects on centrally active catechol amines and their breakdown products. Interest in the biogenic amines was further enhanced by the development of reliable laboratory measures and by demonstrations that orally administered monoamine-oxidase inhibitors may have favorable effects in the treatment of some mental disorders, particularly depressive states.

Keywords

Depressive State Cholinesterase Activity Anticholinergic Agent Cholinergic Mechanism Perceptual Distortion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dale, H. H.: The Action of Certain Esters and Ethers of Choline, and Their Relation to Muscarine, J. Pharmacol. Exper. Therap. 6: 147, 1914.Google Scholar
  2. 2.
    Dikshit, B. B.: Action of Acetylcholine on the Brain and Its Occurrence Therein, J. Physiol. 80: 409, 1934.PubMedGoogle Scholar
  3. 3.
    Langley, J.N.: The Autonomic Nervous System, W. Heffer and Sons, Ltd., Cambridge, U.K., 1921, 80 pp.Google Scholar
  4. 4.
    Feldberg, W.: Present Views on the Mode of Action of Acetylcholine in the Central Nervous System, Physiol. Rev. 25: 596, 1945.Google Scholar
  5. 5.
    Feldberg, W.: The Role of Acetylcholine in the Central Nervous System, Brit, Med. Bull. 6: 312, 1950.Google Scholar
  6. 6.
    Hughes, R. A., and Robinson, F.: Acetylcholine and the Central Nervous System. A Review of Neurochemical Mechanisms, Yale J. Biol. Med. 24: 35–47, 1951.Google Scholar
  7. 7.
    Longo, V. G.: Acetylcholine, Cholinergic Drugs, and Cortical Electrical Activity, Experientia 11: 76–78, 1955.PubMedCrossRefGoogle Scholar
  8. 8.
    Nachmansohn, D.: Chemical and Molecular Basis of Nerve Activity, Academic Press, New York, 1959.Google Scholar
  9. 9.
    Nachmansohn, D.: Chemical Factors Controlling Nerve Activity, Science 134: 1962–1968, 1961.PubMedCrossRefGoogle Scholar
  10. 10.
    Rinaldi, F., and Himwich, H. E.: Alerting Responses and Actions of Atropine and Cholinergic Drugs, Arch. Neurol. Psychiat. 73: 387–395, 1955.Google Scholar
  11. 11.
    Rinaldi, F., and Himwich, H. E.: Cholinergic Mechanism Involved in Function of Mesodiencephalic Activating System, Arch. Neurol. Psychiat. 73: 396–402, 1955.Google Scholar
  12. 12.
    White, R. P.: Relationship Between Cholinergic Drugs and EEG Activation, Arch. Intern. Pharmacodyn. 145: 1–17, 1963.Google Scholar
  13. 13.
    Whitteridge, D.: The Role of Acetylcholine in Synaptic Transmission: A Critical Review, J. Neurol. Neurosurg. Psychiat. 11: 134, 1948.PubMedCrossRefGoogle Scholar
  14. 14.
    Freedman, A. M., Bales, P.D., Willis, A., and Himwich, H. E.: Experimental Production of Electrical Major Convulsive Patterns, Am. J. Physiol. 156: 117, 1949.PubMedGoogle Scholar
  15. 15.
    Grob, D., Harvey, A.M., Langworthy, O. R., and Lilienthal, J. L., Jr.: The Administration of Di-isopropyl Fluorophosphate (DFP) to Man. III. Effect on the Central Nervous System with Special Reference to the Electrical Activity of the Brain, Bull. Johns Hopkins Hosp. 81: 257–266, 1947.PubMedGoogle Scholar
  16. 16.
    Grob, D., and Harvey, J. C.: Effects in Man of the Anticholinesterase Compound Sarin, J. Clin. Invest. 37: 350–368, 1958.PubMedCrossRefGoogle Scholar
  17. 17.
    Hampson, J. L., Essig, C. F., McCauley, A., and Himwich, H. E.: Effects of Di-isopropyl Fluoro-phosphate (DFP) on Electroencephalogram and Cholinesterase Activity, Electroencephalog. Clin, Neurophysiol. 2: 41, 1950.Google Scholar
  18. 18.
    Nachmansohn, D., and Feld, E.: Studies on Cholinesterase. IV. On the Mechanism of Di-isopropyl Fluorophosphate Action in vivo, J. Biol. Chem. 171: 715, 1947.PubMedGoogle Scholar
  19. 19.
    Rowntree, D. W., Nevin, S., and Wilson, A.: The Effects of Diisopropylfluorophosphonate in Schizophrenia and Manic Depressive Psychosis, J. Neurol. Neurosurg. Psychiat. 13: 47–59, 1950.PubMedCrossRefGoogle Scholar
  20. 20.
    Bowers, M. B., Jr., Goodman, E., and Sim, V. M.: Some Behavioral Changes in Man Following Anticholinesterase Administration, J. Nervous Mental Disease 138: 383–389, 1964.CrossRefGoogle Scholar
  21. 21.
    Gershon, S., and Shaw, F. H.: Psychiatric Sequelae of Chronic Exposure to Organophosphate Insecticides, Lancet 1: 1371–1374, 1961.PubMedCrossRefGoogle Scholar
  22. 22.
    Tower, D. B., and McEachern, D.: Acetylcholine and Neuronal Activity in Cranio-Cerebral Trauma, T. Clin. Invest. 27: 558, 1948.Google Scholar
  23. 23.
    Tower, D. B., and McEachern, D.: Acetycholine and Neuronal Activity: Acetylcholine and Cholinesterase Activity in the Cerebrospinal Fluids of Patients with Epilepsy, Can. J. Res. 27 (E): 120, 1949.Google Scholar
  24. 24.
    Ward, A. A.: Atropine in the Treatment of Closed Head Injury, J. Neurosurg. 7: 398–402, 1950.PubMedCrossRefGoogle Scholar
  25. 25.
    Jenkner, F. L., and Lechner, H.: Über den Einfluss von Scopolamin auf das Elektroenzephalogramm bei frischer gedeckter Hirnschädigung, Fortschr. Neurol. Psychiat. 22: 270–276, 1954.Google Scholar
  26. 26.
    Forrer, G. R.: Atropine Toxicity in the Treatment of Mental Disease, Am. J. Psychiat. 108: 107–112, 1951.PubMedGoogle Scholar
  27. 27.
    Abood, L.G., Ostfeld, A.M., and Biel, J.: A New Group of Psychotomimetic Agents, Proc. Soc. Exptl. Biol. Med. 97; 483–486, 1958.CrossRefGoogle Scholar
  28. 28.
    White, R. P., and Carlton, R. A.: Evidence Indicating Central Atropine-Like Actions of Psychotogenic Piperidyl-Benzilates, Psychopharmacologia 4: 459–471, 1963.PubMedCrossRefGoogle Scholar
  29. 29.
    White, R. P., and Westerbeke, E. J.: Differences in Central Anticholinergic Actions of Phenothiazine Derivatives, Exptl. Neurol. 4: 317–329, 1961.Google Scholar
  30. 30.
    Leuner, H.: Über die Ursachen von Bewusstseinstorungen bei experimentellen Psychosen, Med. Exptl. 5: 224, 1961.Google Scholar
  31. 31.
    Wilson, R. E., and Shagass, C.: Comparison of Two Drugs with Psychotomimetic Effects (LSD and Ditran), J. Nervous Mental Disease 138: 277–286, 1964.CrossRefGoogle Scholar
  32. 32.
    Wilson, W. P., and Hughes, J. L.: Observations of the Effects of JB-329 (Ditran) on the Electroencephalogram of Man, J. Neuropsychiat. 5: 310–315, 1964.PubMedGoogle Scholar
  33. 33.
    Ulett, G. A., and Johnson, M. W.: Effect of Atropine and Scopolamine upon Electroencephalographic Changes Induced by Electroconvulsive Therapy, Electroencephalog, Clin. Neurophysiol. 9: 217–224, 1957.Google Scholar
  34. 34.
    Johnson, L. C., Ulett, G. A., Johnson, M., Smith, K., and Sines, J.O.: Electroconvulsive Therapy (with and without Atropine). Effect on Electronically Analyzed Electroencephalogram, Arch, Gen. Psychiat. 2: 324–336, 1960.Google Scholar
  35. 35.
    Fink, M.: Effect of Anticholinergic Compounds on Post-Convulsive Electroencephalogram and Behavior of Psychiatric Patients, Electroencephalog. Clin. Neurophysiol. 12: 359–369, 1960.Google Scholar
  36. 36.
    Fink, M.: Effect of Anticholinergic Agent, Diethazine, on EEG and Behavior; Significance for Theory of Convulsive Therapy, Arch. Neurol. Psychiat. 80: 380–387, 1958.Google Scholar
  37. 37.
    Bornstein, M. B.: Presence and Action of Acetylcholine in Experimental Brain Trauma, J. Neurophysiol. 9: 349, 1946.PubMedGoogle Scholar
  38. 38.
    Sachs, E., Jr.: Acetylcholine and Serotonin in the Spinal Fluid, J. Neurosurg. 14: 22, 1957.PubMedCrossRefGoogle Scholar
  39. 39.
    Abood, L. G., and Meduna, L. J.: Some Effects of a New Psychotogen in Depressive States, J. Nervous Mental Disease 127: 546–549, 1958.CrossRefGoogle Scholar
  40. 40.
    Fink, M., Klein, D. F., and Kramer, J. C.: Clinical Efficacy of Chlorpromazine-Procyclidine Combination, Imipramine, and Placebo in Depressive Disorders, Psychopharmacologia 7: 27–36, 1965.PubMedCrossRefGoogle Scholar
  41. 41.
    Flügel, F., and Itil, T.: Klinische elektroenzephalographische Untersuchungen mit “Verwirrtheit” hervorrufenden Substanzen, Psychopharmacologia 3: 79–98, 1962.CrossRefGoogle Scholar
  42. 42.
    Itil, T., Fink, M., Neubauer, H., and Gershon, S.: Drug Induced Dissolution of Cortical Electrical Activity and Its Correlation with Psychopathological Phenomena, in: Bradley, P. B. (editor), Neuro-Psychopharmacology, Volume 4, Elsevier, Amsterdam, 1965 (in press).Google Scholar
  43. 43.
    Biel, J. H., Nuhfer, P. A., Hoya, W. K., Leiyes, H. A., and Abood, L.: A Cholinergic Blockage as an Approach to the Development of New Psychotropic Agent, Ann. N. Y. Acad. Sci. 96: 251–262, 1962.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1966

Authors and Affiliations

  • Max Fink
    • 1
  1. 1.Department of Psychiatry at the Missouri Institute of PsychiatryUniversity of Missouri School of MedicineSt. LouisUSA

Personalised recommendations